In March of 2020, CMS expanded the COVID-19 Accelerated and Advance Payments Program to additional Medicare Part A providers and Part B suppliers in response to the COVID-19 pandemic. READ MORE
(By accessing, browsing or using the pages below, you agree to the Blog Conditions of Use/Disclaimer available under "Links.")
In March of 2020, CMS expanded the COVID-19 Accelerated and Advance Payments Program to additional Medicare Part A providers and Part B suppliers in response to the COVID-19 pandemic. READ MORE
On October 22, HHS updated its reporting guidance to revise the methodology for calculating lost revenue and expanded the eligibility requirements for the Phase 3 distribution. This blog updates our blog posted earlier this week on these topics. READ MORE
The Department of Health and Human Services has opened the portal for Phase 3 of Provider Relief Funds, which will include an additional $20 billion in distributions. The distributions will be made available to an expanded group of providers. READ MORE
Recipients of aid from the Provider Relief Fund are required to submit reports detailing how the funds were used, but detailed instructions and a data collection template have not yet been released. This article outlines what we know about the reporting deadlines while recipients await further guidance. READ MORE
The Department of Health and Human Services has updated its FAQs regarding the Provider Relief Fund contained in the CARES Act. It is important to monitor these changes because HHS has changed its position on certain issues and such changes could impact a provider’s ability to retain the funds. READ MORE
The CARES Act, signed into law on March 27, 2020, provides emergency assistance and health care response for individuals, families and businesses affected by the 2020 coronavirus pandemic. The CARES Act includes several provisions that could provide relief to physicians as a result of the pandemic. READ MORE
NOTICE.
Although we would like to hear from you, we cannot represent you until we know that
doing so will not create a conflict of interest. Also, we cannot treat unsolicited
information as confidential. Accordingly, please do not send us any information
about any matter that may involve you until you receive a written statement from
us that we represent you (an ‘engagement letter’).
By clicking the ‘ACCEPT’ button, you agree that we may review any information you transmit to us. You recognize that our review of your information, even if you submitted it in a good faith effort to retain us, and, further, even if you consider it confidential, does not preclude us from representing another client directly adverse to you, even in a matter where that information could and will be used against you. Please click the ‘ACCEPT’ button if you understand and accept the foregoing statement and wish to proceed.